We compared the rate of prescription of low-dose spironolactone among patients with heart failure in a general medical inpatient setting and in a specialist left ventricular (LV) dysfunction clinic. 38% of general medical patients and 72% of patients attending the specialist clinic had been prescribed spironolactone. When contraindications were considered, 54% of patients in the general medical group and 77% of patients in the specialist clinic group were appropriately treated in respect of spironolactone prescribing. Patients attending a specialist LV dysfunction clinic are therefore more likely to be treated with low dose spironolactone, an accepted appropriate treatment for heart failure, than those admitted to general medical and acute geriatric units.Improvement in care for patients with CHF may be achieved either by increasing the use of specialist clinics or by better dissemination of evolving evidence.
INTRODUCTION
In September 1999, the findings of the Randomized Aldactone Evaluation Study' (RALES) were published. In this double-blind study, 1663 patients with left ventricular ejection fraction less than 35%, an( NYHA symptom class III-IV were randomised to receive either 25mg spironolactone or placebo. The study was discontinued prematurely after two years because interim analysis showed a 30% reduction in risk of death in the group receiving spironolactone. This is equivalent to a number needed to treat of nine to avoid one death during this two year period2. In addition, there was a 35% reduction in risk ofhospitalisation for worsening heart failure (equivalent to a number needed to treat ofeleven) and significant symptomatic improvement in this group. The low cost of spironolactone implied likely cost-effectiveness. RALES therefore defined a standard in heart failure management having demonstrated an important contribution from low dose spironolactone in addition to conventional therapies. We appreciate the importance of applying evidence from clinical studies to practice, and it is therefore reasonable to aim to incorporate spironolactone into the medication of all patients with moderate to severe heart failure, except for the few in whom it is contraindicated. We accept that there is no evidence available at present to support its use in mild CHF. We wished to assess the performance of the specialist left ventricular (LV) dysfunction clinic at the Belfast City Hospital with respect to spironolactone prescribing, comparing this against the prescribing rates for inpatients admitted to the general medical and acute elderly care units.
METHOD
The records of the last 50 patients whose hospital admission was coded with a primary diagnosis of heart failure were analysed prior to 20th February 2000. The 'final' chart related to an admission in December 1999. We also reviewed the records of all 75 patients who were attending the LV dysfunction clinic during the same period. The assumption was made that patients admitted to hospital on the emergency "take-in" due to heart failure and those referred to the specialist clinic Figure 2 ). Therefore 23% of these 75 patients were not receiving spironolactone despite the absence of clear contraindication.
DISCUSSION
The comparisons between the two sets of data are interesting but in some ways surprising. Patients who attended the LV dysfunction clinic were more likely to have been prescribed spironolactone; perhaps this is to be expected since physicians running a specialist clinic are probably more likely to be aware of recent evidence within their discipline. However, when the group which was not prescribed spironolactone in each case is examined, it becomes clear that there is little difference in the reason for its omission. One might have expected that the proportion of patients not receiving spironolactone due to contraindication (rather than oversight or lack of familiarity with current evidence) would have been greater among the LV dysfunction clinic patients; this was not the case. The absolute risk of 'oversight', however, was greater among the general medical patient Spironolactone has been found to decrease the amount of a key marker of vascular collagen turnover and also to bring about a decrease in heart rate.4 Interestingly, this beneficial decrease in heart rate was most prominent in early morning when fatal cardiac events are known to be most common.
Spironolactone has also been shown to improve vascular endothelial dysfunction (characterised by improved responsiveness to vasoactive agents) and also to inhibit the conversion of angiotensin I to angiotensin 11.7 Perhaps such effects may account at least in part for the mortality benefits of aldosterone antagonism identified in the RALES1.
It is therefore well established that hyperaldosteronism has an adverse effect on cardiac function, one which may be avoided by the use of aldosterone antagonists. For many years it has been assumed that since ACE inhibitors block aldosterone production spironolactone is unnecessary8; however, the finding that it reduced mortality by 30% over a two-year period with concomitant reduction in morbidity must not be ignored. It not documented. It is not appropriate to presumptively extrapolate these findings to other heart failure treatment interventions, nor to imply actual outcome differences between the two groups; however, our findings support in at least one facet the argument for having teams with a special interest in managing patients with heart failure. This is further supported by data from
Chin et all' identifying an analogous situation relating to ACE inhibitor therapy, whereby general practitioners and general physicians were found to underuse these drugs when compared to cardiologists.
CONCLUSION
Low dose spironolactone has been identified as a safe and rational therapy which decreases mortality, improves symptoms and reduces hospitalisations (thus producing resource utilisation benefits) when added to conventional treatment in patients with moderate-to-severe CHF. When measured against this standard, the finding that we adequately treat only 54% of heart failure patients in a general medical inpatient setting and 77% of patients attending a specialist LV dysfunction clinic provides us with a point from which we might expect to improve; one might alternatively reason that this reflects surprisingly impressive receptiveness to new data over a relatively short time. We have a duty to raise the standard of care for patients with CHF, either by increasing the use of specialist clinics or by improving general physicians' awareness of evolving evidence.
